Fig. 5From: Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemiasResponse frequencies for the preferred formulation of deferasirox at week 2 (start of treatment) and end of treatment by treatment arm. Numbers indicate the number of patients in each response category; *n < 5 patients; DT, dispersible tablet; FCT, film-coated tabletBack to article page